The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.

A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients.

The US FDA has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin.

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around four in every 10 patients treated with these drugs, suggests a pooled data analysis of the ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.

Explore how chemotherapy causes peripheral neuropathy in 40% of cancer patients. Learn about the risk factors and the need ...

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...

Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more ...

Have you experienced pain or tingling in your hands or feet? Those are signs of possible neuropathy, “a general term for ...